This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Cefodizime is a broad-spectrum, third-generation cephalosporin used to treat serious infections caused by susceptible bacteria.
- Generic Name
- Cefodizime
- DrugBank Accession Number
- DB13470
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Cefodizime (DB13470)
- Weight
- Average: 584.669
Monoisotopic: 584.027629784 - Chemical Formula
- C20H20N6O7S4
- Synonyms
- CDZM
- Cefodizima
- Cefodizime
- Cefodizimum
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Gram-negative infections bacterial infections •••••••••••• •••••••••• ••••••• ••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Cefodizime may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefodizime. Aceclofenac The risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Cefodizime. Acemetacin The risk or severity of nephrotoxicity can be increased when Cefodizime is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Cefodizime is combined with Acenocoumarol. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Cefodizime sodium HC1T51593A 86329-79-5 WBOBLQIRACJNPA-AEKYOGSZSA-L
Categories
- ATC Codes
- J01DD09 — Cefodizime
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Lactams
- Sub Class
- Beta lactams
- Direct Parent
- Cephalosporins
- Alternative Parents
- N-acyl-alpha amino acids and derivatives / 2,4,5-trisubstituted thiazoles / 2,4-disubstituted thiazoles / Alkylarylthioethers / 1,3-thiazines / 2-amino-1,3-thiazoles / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides show 12 more
- Substituents
- 1,3-thiazol-2-amine / 2,4,5-trisubstituted 1,3-thiazole / 2,4-disubstituted 1,3-thiazole / Alkylarylthioether / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aromatic heteropolycyclic compound / Aryl thioether show 28 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- cephalosporin, 1,3-thiazole, oxime O-ether (CHEBI:63214)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Z31298J4HQ
- CAS number
- 69739-16-8
- InChI Key
- XDZKBRJLTGRPSS-BGZQYGJUSA-N
- InChI
- InChI=1S/C20H20N6O7S4/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32)/b25-12-/t13-,17-/m1/s1
- IUPAC Name
- (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-({[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- SMILES
- [H][C@]12SCC(CSC3=NC(C)=C(CC(O)=O)S3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
References
- General References
- AIFA Product Information: Modivid (cefodizime) powder for solution for injection [Link]
- External Links
- Human Metabolome Database
- HMDB0041850
- KEGG Drug
- D07643
- ChemSpider
- 4514859
- BindingDB
- 50422690
- 20485
- ChEBI
- 63214
- ChEMBL
- CHEMBL2303613
- ZINC
- ZINC000003830421
- Wikipedia
- Cefodizime
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intramuscular; Parenteral 1 G/4ML Injection, powder, for solution Intravenous; Parenteral 2 G/10ML Injection, powder, for solution Parenteral 1 G/4ML Injection, powder, for solution Parenteral 250 MG/2ML Injection, powder, for solution Parenteral 500 MG/2ML - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.068 mg/mL ALOGPS logP 1.07 ALOGPS logP 0.24 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 2.68 Chemaxon pKa (Strongest Basic) 3.45 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 11 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 197.4 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 136.93 m3·mol-1 Chemaxon Polarizability 56.47 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 236.4096269 predictedDarkChem Lite v0.1.0 [M-H]- 231.0667269 predictedDarkChem Lite v0.1.0 [M-H]- 217.94565 predictedDeepCCS 1.0 (2019) [M+H]+ 233.4500269 predictedDarkChem Lite v0.1.0 [M+H]+ 229.7883269 predictedDarkChem Lite v0.1.0 [M+H]+ 219.77055 predictedDeepCCS 1.0 (2019) [M+Na]+ 235.1909269 predictedDarkChem Lite v0.1.0 [M+Na]+ 231.1189269 predictedDarkChem Lite v0.1.0 [M+Na]+ 225.37637 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:42 / Updated at May 05, 2021 20:31